Eli Lilly drug prolongs patients' lives in lung cancer trial

02/20/2014 | Reuters

A late-stage trial showed Eli Lilly and Co.'s experimental drug ramucirumab, in combination with docetaxel, significantly improved survival and progression-free survival in patients with non-small cell lung cancer compared with a combination of placebo and docetaxel. Eli Lilly plans to submit the drug for regulatory review for this indication later this year. Ramucirumab is also under development for treatment of liver cancer and colorectal cancer.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Fort Worth, TX
Senior Scientist - Cell Engineering Group
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC